Please login to the form below

Not currently logged in
Email:
Password:

Endo pain drug gets priority review

Endo Pharmaceuticals has been granted a priority review by the US Food and Drug Administration for a new formulation of its pain drug oxymorphone

Endo Pharmaceuticals has been granted a priority review by the US Food and Drug Administration (FDA) for a new formulation of its pain drug oxymorphone that is designed to prevent abuse.

The new tablet is made to resist crushing, breaking, powdering or pulverising.

Priority review, which is reserved for drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists, means that the FDA aims to act on a New Drug Application (NDA) within six months rather than the standard 10 to 12 months. The FDA has set January 7, 2011 as the action date for the Endo product.

This new formulation of the long-acting drug is a semi-synthetic opioid analgesic for treatment of moderate-to-severe chronic pain in patients requiring continuous pain relief over an extended period of time.

Endo has marketed oxymorphone in the US since 1959. It sells the drug under the brandnames Opana and Opana ER.

23rd September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
...
Can eLearning improve patient recruitment and retention?
Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...

Infographics